Among Greek patients with breast and ovarian cancer, BRCA1 and BRCA2 LGRs alone comprise up to 24% of pathogenic variants identified in BRCA1 and BRCA2 [39,40,41,42,43,44,45]. This evidence concerns the gene BRCA1 and ovarian cancer.